期刊
CYTOGENETIC AND GENOME RESEARCH
卷 161, 期 6-7, 页码 362-371出版社
KARGER
DOI: 10.1159/000516530
关键词
Cancer (epi)genomic landscapes; Intratumor heterogeneity; Cancer evolution; Liquid biopsy; Circulating tumor DNA
The goal of personalized cancer medicine is to identify specific mutations with prognostic and therapeutic value for tailor-made therapy. However, the main obstacle lies in intratumor heterogeneity and clonal evolution, which can lead to drug resistance. New technologies like next-generation sequencing play a crucial role in profiling cancer (epi)genomic landscapes.
The goal in personalized therapeutic approaches for cancer medicine is to identify specific mutations with prognostic and therapeutic value in order to tailor the therapy for the single patient. The most powerful obstacle for personalized medicine arises from intratumor heterogeneity and clonal evolution, which can promote drug resistance. In this scenario, new technologies, such as next-generation sequencing, have emerged as a central diagnostic tool to profile cancer (epi)genomic landscapes. Therefore, a better understanding of the biological mechanisms underlying cancer evolution is mandatory and represents the current challenge to accurately predict whether cancer will recur after chemotherapy with the aim to tailor rational therapeutic approaches.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据